Uppsala, Sweden, April 25, 2025. Resitu, a Swedish company developing pioneering devices for full excision of breast tumors, has appointed Åsa Runnäs as the company’s CEO, building on her 20 years of experience in device regulation and commercialization.

 

Åsa Runnäs is one of Resitu’s core investors, part of its founding team, and has served as the company’s chief strategy officer. Prior to Resitu, she was CEO of several medtech consultancy firms.

 

The news comes as Resitu prepares for the launch of its first device, a vacuum-assisted, minimally invasive, handheld instrument for the excision of breast lesions for diagnostic analysis.

 

Resitu recently demonstrated its device to 40 leading breast surgeons at the Uppsala Breast Meeting, held at Uppsala University in Sweden. During guided workshops, the surgeons experienced hands-on use of Resitu’s devices.

 

“We are very encouraged by the feedback from surgeons at the workshop. It reinforces our view that the Resitu devices will play an important role in breast tumor management,” commented Åsa Runnäs. “The feedback also confirms that Resitu’s devices are easy to use, applicable to a wide patient population, and an important response to an unmet global need.”

 

Demand will be high. The instrument is developed by renowned surgeons, and the company’s absolute focus is to ensure that healthcare systems around the world will be able to access the device as soon as possible.

 

“By radically rethinking breast tumor management, we will be able to offer healthcare providers a much-needed excision-led, minimal invasive approach for large tissue removal. This solution will not only ease the strain on healthcare systems but, most importantly, it will shorten the stressful time patients experience during the diagnostic process. This is the way forward for 21^st Century care,” added Runnäs.